{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T06:26:57Z","timestamp":1757312817117,"version":"3.37.3"},"reference-count":213,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T00:00:00Z","timestamp":1699833600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T00:00:00Z","timestamp":1699833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-023-02225-0","type":"journal-article","created":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T16:02:33Z","timestamp":1699891353000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Molecular insight into renal cancer and latest therapeutic approaches to tackle it: an\u00a0updated\u00a0review"],"prefix":"10.1007","volume":"40","author":[{"given":"Reshma","family":"Murali","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0780-0492","authenticated-orcid":false,"given":"Abilash Valsala","family":"Gopalakrishnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,13]]},"reference":[{"issue":"1","key":"2225_CR1","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3390\/life12010024","volume":"12","author":"N Kathuria-Prakash","year":"2021","unstructured":"Kathuria-Prakash N, Drolen C, Hannigan CA, Drakaki A. Immunotherapy and metastatic renal cell carcinoma: a review of new treatment approaches. Life Basel. 2021;12(1):24.","journal-title":"Life Basel"},{"issue":"4","key":"2225_CR2","doi-asserted-by":"crossref","first-page":"167.e9","DOI":"10.1016\/j.urolonc.2015.10.011","volume":"34","author":"Y Lotan","year":"2016","unstructured":"Lotan Y, et al. Renal-cell carcinoma risk estimates based on participants in the prostate, lung, colorectal, and ovarian cancer screening trial and national lung screening trial. Urol Oncol. 2016;34(4):167.e9-16.","journal-title":"Urol Oncol"},{"issue":"1","key":"2225_CR3","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/ijc.20618","volume":"114","author":"JD Hunt","year":"2005","unstructured":"Hunt JD, van der Hel OL, McMillan GP, Boffetta P, Brennan P. Renal cell carcinoma in relation to cigarette smoking: meta-analysis of 24 studies. Int J Cancer. 2005;114(1):101\u20138.","journal-title":"Int J Cancer"},{"issue":"5","key":"2225_CR4","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.eururo.2015.01.005","volume":"67","author":"B Ljungberg","year":"2015","unstructured":"Ljungberg B, et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol. 2015;67(5):913\u201324.","journal-title":"Eur Urol"},{"key":"2225_CR5","volume-title":"Diagnosis and surgical management of renal tumors","author":"AR Meyer","year":"2019","unstructured":"Meyer AR, Allaf ME, Gorin MA. Epidemiology and risk factors of renal cell carcinoma. In: Gorin M, Allaf M, editors. Diagnosis and surgical management of renal tumors. Cham: Springer; 2019."},{"issue":"2","key":"2225_CR6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11934-020-0962-9","volume":"21","author":"J Oto","year":"2020","unstructured":"Oto J, et al. Urinary microRNAs: looking for a new tool in diagnosis, prognosis, and monitoring of renal cancer. Curr Urol Rep. 2020;21(2):11.","journal-title":"Curr Urol Rep"},{"issue":"9","key":"2225_CR7","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nrurol.2014.194","volume":"11","author":"JR Bhatt","year":"2014","unstructured":"Bhatt JR, Finelli A. Landmarks in the diagnosis and treatment of renal cell carcinoma. Nat Rev Urol. 2014;11(9):517\u201325.","journal-title":"Nat Rev Urol"},{"issue":"6","key":"2225_CR8","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.eururo.2017.04.011","volume":"72","author":"JM Jones","year":"2017","unstructured":"Jones JM, et al. Setting research priorities for kidney cancer. Eur Urol. 2017;72(6):861\u20134.","journal-title":"Eur Urol"},{"issue":"9","key":"2225_CR9","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s00345-018-2286-7","volume":"36","author":"SH Rossi","year":"2018","unstructured":"Rossi SH, Klatte T, Usher-Smith J, Stewart GD. Epidemiology and screening for renal cancer. World J Urol. 2018;36(9):1341\u201353.","journal-title":"World J Urol"},{"issue":"10","key":"2225_CR10","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1097\/PAS.0b013e318299f0fb","volume":"37","author":"B Delahunt","year":"2013","unstructured":"Delahunt B, et al. The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol. 2013;37(10):1490\u2013504.","journal-title":"Am J Surg Pathol"},{"key":"2225_CR11","doi-asserted-by":"crossref","unstructured":"Comprehensive molecular characterization of papillary renal-cell carcinoma. NEJM 374(2):135\u2013145, 2015.","DOI":"10.1056\/NEJMoa1505917"},{"issue":"6","key":"2225_CR12","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/sj.onc.1206153","volume":"22","author":"K Yamazaki","year":"2003","unstructured":"Yamazaki K, Sakamoto M, Ohta T, Kanai Y, Ohki M, Hirohashi S. Overexpression of KIT in chromophobe renal cell carcinoma. Oncogene. 2003;22(6):847\u201352.","journal-title":"Oncogene"},{"issue":"11","key":"2225_CR13","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/nrc2502","volume":"8","author":"WG Kaelin Jr","year":"2008","unstructured":"Kaelin WG Jr. The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. Nat Rev Cancer. 2008;8(11):865\u201373.","journal-title":"Nat Rev Cancer"},{"key":"2225_CR14","unstructured":"U. Food and D. Administration, \"FDA approves avelumab plus axitinib for renal cell carcinoma,\" ed, 2021."},{"issue":"6","key":"2225_CR15","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1016\/j.juro.2014.07.099","volume":"192","author":"C Ellimoottil","year":"2014","unstructured":"Ellimoottil C, et al. New modalities for evaluation and surveillance of complex renal cysts. J Urol. 2014;192(6):1604\u201311.","journal-title":"J Urol"},{"issue":"3","key":"2225_CR16","first-page":"179","volume":"99","author":"RE Gray","year":"2019","unstructured":"Gray RE, Harris GT. Renal cell carcinoma: diagnosis and management. Am Fam Phys. 2019;99(3):179\u201384.","journal-title":"Am Fam Phys"},{"issue":"9745","key":"2225_CR17","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/S0140-6736(10)60956-7","volume":"376","author":"S Shah","year":"2010","unstructured":"Shah S, Watnick T, Atta MG. Not all renal cysts are created equal. Lancet. 2010;376(9745):1024.","journal-title":"Lancet"},{"issue":"10021","key":"2225_CR18","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/S0140-6736(15)00046-X","volume":"387","author":"U Capitanio","year":"2016","unstructured":"Capitanio U, Montorsi F. Renal cancer. Lancet. 2016;387(10021):894\u2013906.","journal-title":"Lancet"},{"issue":"4","key":"2225_CR19","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41571-020-00455-z","volume":"18","author":"DA Braun","year":"2021","unstructured":"Braun DA, et al. Beyond conventional immune-checkpoint inhibition\u2014novel immunotherapies for renal cell carcinoma. Nat Rev Clin Oncol. 2021;18(4):199\u2013214.","journal-title":"Nat Rev Clin Oncol"},{"key":"2225_CR20","doi-asserted-by":"crossref","first-page":"118632","DOI":"10.1016\/j.lfs.2020.118632","volume":"264","author":"D Singh","year":"2021","unstructured":"Singh D. Current updates and future perspectives on the management of renal cell carcinoma. Life Sci. 2021;264:118632.","journal-title":"Life Sci"},{"issue":"4","key":"2225_CR21","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.eururo.2021.12.010","volume":"81","author":"TO Bui","year":"2022","unstructured":"Bui TO, Dao VT, Nguyen VT, Feugeas JP, Pamoukdjian F, Bousquet G. Genomics of clear-cell renal cell carcinoma: a systematic review and meta-analysis. Eur Urol. 2022;81(4):349\u201361.","journal-title":"Eur Urol"},{"key":"2225_CR22","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.euros.2021.12.007","volume":"37","author":"NA Bosma","year":"2022","unstructured":"Bosma NA, et al. Efficacy and safety of first-line systemic therapy for metastatic renal cell carcinoma: a systematic review and network meta-analysis. Eur Urol Open Sci. 2022;37:14\u201326.","journal-title":"Eur Urol Open Sci"},{"issue":"3","key":"2225_CR23","doi-asserted-by":"crossref","first-page":"e024691","DOI":"10.1136\/bmjopen-2018-024691","volume":"9","author":"C Karner","year":"2019","unstructured":"Karner C, Kew K, Wakefield V, Masento N, Edwards SJ. Targeted therapies for previously treated advanced or metastatic renal cell carcinoma: systematic review and network meta-analysis. BMJ Open. 2019;9(3):e024691.","journal-title":"BMJ Open"},{"key":"2225_CR24","unstructured":"Pandey J, Syed W. Renal Cancer. In: StatPearls. StatPearls Publishing, Treasure Island (FL); 2022."},{"issue":"23","key":"2225_CR25","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1056\/NEJMoa1611406","volume":"375","author":"A Ravaud","year":"2016","unstructured":"Ravaud A, et al. Adjuvant Sunitinib in high-risk renal-cell carcinoma after nephrectomy. N Engl J Med. 2016;375(23) 2246\u201354.","journal-title":"N Engl J Med."},{"issue":"10032","key":"2225_CR26","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/S0140-6736(16)00559-6","volume":"387","author":"B Naomi","year":"2016","unstructured":"Naomi B, et al. Adjuvant sunitinib or sorafenib for high-risk non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind placebo-controlled randomised phase 3 trial. The Lancet. 2016;387(10032):2008\u201316.","journal-title":"The Lancet."},{"issue":"35","key":"2225_CR27","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1200\/JCO.2017.73.5324","volume":"35","author":"J Motzer","year":"2017","unstructured":"Motzer J, et al.  Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma. J Clin Oncol. 2017;35(35) 3916\u201323.","journal-title":"J Clin Oncol."},{"issue":"12","key":"2225_CR28","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1093\/annonc\/mdy454","volume":"29","author":"M Gross-Goupil","year":"2018","unstructured":"Gross-Goupil M, et al. Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III randomized ATLAS trial. Ann Oncol. 2018;29(12) 2371\u20138.","journal-title":"Ann Oncol."},{"key":"2225_CR29","unstructured":"(2021, 2023). SEER cancer stat facts: kidney and renal pelvis cancer."},{"key":"2225_CR30","unstructured":"E. M. Ferlay JSI, Dikshit R. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11. http:\/\/globocan.iarc.fr (2013)"},{"issue":"16","key":"2225_CR31","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.3390\/cancers14164059","volume":"14","author":"T Makino","year":"2022","unstructured":"Makino T, et al. Epidemiology and prevention of renal cell carcinoma. Cancers (Basel). 2022;14(16):4059.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"2225_CR32","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.3390\/ijms22062832","volume":"22","author":"MP Scholtes","year":"2021","unstructured":"Scholtes MP, Alberts AR, Ifl\u00e9 IG, Verhagen PC, van der Veldt AA, Zuiverloon TC. Biomarker-oriented therapy in bladder and renal cancer. Int J Mol Sci. 2021;22(6):2832.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2225_CR33","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.eururo.2014.10.002","volume":"67","author":"A Znaor","year":"2015","unstructured":"Znaor A, Lortet-Tieulent J, Laversanne M, Jemal A, Bray F. International variations and trends in renal cell carcinoma incidence and mortality. Eur Urol. 2015;67(3):519\u201330.","journal-title":"Eur Urol"},{"issue":"8","key":"2225_CR34","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/j.1464-410X.2008.07451.x","volume":"101","author":"F Levi","year":"2008","unstructured":"Levi F, et al. The changing pattern of kidney cancer incidence and mortality in Europe. BJU Int. 2008;101(8):949\u201358.","journal-title":"BJU Int"},{"issue":"1","key":"2225_CR35","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3322\/caac.21208","volume":"64","author":"R Siegel","year":"2014","unstructured":"Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9\u201329.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"2225_CR36","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21387","volume":"67","author":"RL Siegel","year":"2017","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7\u201330.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"2225_CR37","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.juro.2008.06.037","volume":"180","author":"RH Thompson","year":"2008","unstructured":"Thompson RH, et al. Renal cell carcinoma in young and old patients\u2013is there a difference? J Urol. 2008;180(4):1262\u20136 (discussion 1266).","journal-title":"J Urol"},{"issue":"3","key":"2225_CR38","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41581-019-0210-z","volume":"16","author":"C Yong","year":"2020","unstructured":"Yong C, Stewart GD, Frezza C. Oncometabolites in renal cancer. Nat Rev Nephrol. 2020;16(3):156\u201372.","journal-title":"Nat Rev Nephrol"},{"issue":"7456","key":"2225_CR39","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/nature12222","volume":"499","author":"CGAR Network","year":"2013","unstructured":"Network CGAR. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013;499(7456):43\u20139.","journal-title":"Nature"},{"issue":"1","key":"2225_CR40","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1038\/s41467-017-01965-8","volume":"8","author":"W Du","year":"2017","unstructured":"Du W, et al. HIF drives lipid deposition and cancer in ccRCC via repression of fatty acid metabolism. Nat Commun. 2017;8(1):1769.","journal-title":"Nat Commun"},{"issue":"7381","key":"2225_CR41","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nature10642","volume":"481","author":"AR Mullen","year":"2011","unstructured":"Mullen AR, et al. Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature. 2011;481(7381):385\u20138.","journal-title":"Nature"},{"issue":"7","key":"2225_CR42","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1002\/ijc.33435","volume":"148","author":"H Wang","year":"2021","unstructured":"Wang H, et al. Oncometabolite L-2-hydroxyglurate directly induces vasculogenic mimicry through PHLDB2 in renal cell carcinoma. Int J Cancer. 2021;148(7):1743\u201355.","journal-title":"Int J Cancer"},{"issue":"35","key":"2225_CR43","doi-asserted-by":"crossref","first-page":"24691","DOI":"10.1074\/jbc.M114.568162","volume":"289","author":"K Shanmugasundaram","year":"2014","unstructured":"Shanmugasundaram K, Nayak B, Shim EH, Livi CB, Block K, Sudarshan S. The oncometabolite fumarate promotes pseudohypoxia through noncanonical activation of NF-\u03baB signaling. J Biol Chem. 2014;289(35):24691\u20139.","journal-title":"J Biol Chem"},{"key":"2225_CR44","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41698-018-0053-2","volume":"2","author":"CR McEvoy","year":"2018","unstructured":"McEvoy CR, et al. SDH-deficient renal cell carcinoma associated with biallelic mutation in succinate dehydrogenase A: comprehensive genetic profiling and its relation to therapy response. NPJ Precis Oncol. 2018;2:9.","journal-title":"NPJ Precis Oncol"},{"issue":"11","key":"2225_CR45","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1158\/2159-8290.CD-13-0696","volume":"4","author":"EH Shim","year":"2014","unstructured":"Shim EH, et al. L-2-Hydroxyglutarate: an epigenetic modifier and putative oncometabolite in renal cancer. Cancer Discov. 2014;4(11):1290\u20138.","journal-title":"Cancer Discov"},{"issue":"5","key":"2225_CR46","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nrurol.2010.47","volume":"7","author":"WM Linehan","year":"2010","unstructured":"Linehan WM, Srinivasan R, Schmidt LS. The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol. 2010;7(5):277\u201385.","journal-title":"Nat Rev Urol"},{"issue":"7","key":"2225_CR47","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1158\/1541-7786.MCR-16-0115","volume":"14","author":"SM Haake","year":"2016","unstructured":"Haake SM, Weyandt JD, Rathmell WK. Insights into the genetic basis of the renal cell carcinomas from the cancer genome atlas. Mol Cancer Res. 2016;14(7):589\u201398.","journal-title":"Mol Cancer Res"},{"issue":"5","key":"2225_CR48","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1053\/j.seminoncol.2016.09.001","volume":"43","author":"LS Schmidt","year":"2016","unstructured":"Schmidt LS, Linehan WM. Genetic predisposition to kidney cancer. Semin Oncol. 2016;43(5):566\u201374.","journal-title":"Semin Oncol"},{"issue":"1","key":"2225_CR49","doi-asserted-by":"crossref","first-page":"188559","DOI":"10.1016\/j.bbcan.2021.188559","volume":"1876","author":"S Chakraborty","year":"2021","unstructured":"Chakraborty S, Balan M, Sabarwal A, Choueiri TK, Pal S. Metabolic reprogramming in renal cancer: events of a metabolic disease. Biochim Biophys Acta Rev Cancer. 2021;1876(1):188559.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"12","key":"2225_CR50","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1158\/0008-5472.CAN-14-1703","volume":"75","author":"HI Wettersten","year":"2015","unstructured":"Wettersten HI, et al. Grade-dependent metabolic reprogramming in kidney cancer revealed by combined proteomics and metabolomics analysis. Cancer Res. 2015;75(12):2541\u201352.","journal-title":"Cancer Res"},{"issue":"23","key":"2225_CR51","doi-asserted-by":"crossref","first-page":"6746","DOI":"10.1158\/0008-5472.CAN-17-0930","volume":"77","author":"O Abu Aboud","year":"2017","unstructured":"Abu Aboud O, et al. Glutamine addiction in kidney cancer suppresses oxidative stress and can be exploited for real-time imaging. Cancer Res. 2017;77(23):6746\u201358.","journal-title":"Cancer Res"},{"issue":"3","key":"2225_CR52","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.juro.2008.04.135","volume":"180","author":"A Horiguchi","year":"2008","unstructured":"Horiguchi A, Asano T, Asano T, Ito K, Sumitomo M, Hayakawa M. Fatty acid synthase over expression is an indicator of tumor aggressiveness and poor prognosis in renal cell carcinoma. J Urol. 2008;180(3):1137\u201340.","journal-title":"J Urol"},{"issue":"2","key":"2225_CR53","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/em.20588","volume":"52","author":"KT Chung","year":"2011","unstructured":"Chung KT, Gadupudi GS. Possible roles of excess tryptophan metabolites in cancer. Environ Mol Mutagen. 2011;52(2):81\u2013104.","journal-title":"Environ Mol Mutagen"},{"issue":"5","key":"2225_CR54","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1089\/omi.2010.0094","volume":"15","author":"K Kim","year":"2011","unstructured":"Kim K, Taylor SL, Ganti S, Guo L, Osier MV, Weiss RH. Urine metabolomic analysis identifies potential biomarkers and pathogenic pathways in kidney cancer. OMICS. 2011;15(5):293\u2013303.","journal-title":"OMICS"},{"issue":"14","key":"2225_CR55","doi-asserted-by":"crossref","first-page":"3471","DOI":"10.1158\/0008-5472.CAN-11-3105","volume":"72","author":"S Ganti","year":"2012","unstructured":"Ganti S, et al. Kidney tumor biomarkers revealed by simultaneous multiple matrix metabolomics analysis. Cancer Res. 2012;72(14):3471\u20139.","journal-title":"Cancer Res"},{"issue":"4","key":"2225_CR56","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1002\/ijc.22322","volume":"120","author":"C-Y Yoon","year":"2007","unstructured":"Yoon C-Y, et al. Renal cell carcinoma does not express argininosuccinate synthetase and is highly sensitive to arginine deprivation via arginine deiminase. Int J Cancer. 2007;120(4):897\u2013905.","journal-title":"Int J Cancer"},{"issue":"7","key":"2225_CR57","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1002\/1878-0261.12499","volume":"13","author":"B Felipe-Abrio","year":"2019","unstructured":"Felipe-Abrio B, Verdugo-Sivianes EM, Carnero A. c-MYB- and PGC1a-dependent metabolic switch induced by MYBBP1A loss in renal cancer. Mol Oncol. 2019;13(7):1519\u201333.","journal-title":"Mol Oncol"},{"issue":"1","key":"2225_CR58","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1186\/s12935-021-02396-8","volume":"21","author":"HE Marei","year":"2021","unstructured":"Marei HE, et al. p53 signaling in cancer progression and therapy. Cancer Cell Int. 2021;21(1):703.","journal-title":"Cancer Cell Int"},{"issue":"3","key":"2225_CR59","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.cell.2009.04.037","volume":"137","author":"KH Vousden","year":"2009","unstructured":"Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell. 2009;137(3):413\u201331.","journal-title":"Cell"},{"issue":"39","key":"2225_CR60","doi-asserted-by":"crossref","first-page":"37722","DOI":"10.1074\/jbc.M301979200","volume":"278","author":"R Tomasini","year":"2003","unstructured":"Tomasini R, et al. TP53INP1s and homeodomain-interacting protein kinase-2 (HIPK2) are partners in regulating p53 activity. J Biol Chem. 2003;278(39):37722\u20139.","journal-title":"J Biol Chem"},{"issue":"10","key":"2225_CR61","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1101\/gad.1291305","volume":"19","author":"X Lu","year":"2005","unstructured":"Lu X, Nannenga B, Donehower LA. PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints. Genes Dev. 2005;19(10):1162\u201374.","journal-title":"Genes Dev"},{"issue":"4","key":"2225_CR62","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/sj.emboj.7601560","volume":"26","author":"ND Marchenko","year":"2007","unstructured":"Marchenko ND, Wolff S, Erster S, Becker K, Moll UM. Monoubiquitylation promotes mitochondrial p53 translocation. Embo j. 2007;26(4):923\u201334.","journal-title":"Embo j"},{"issue":"12","key":"2225_CR63","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.4161\/cc.10.12.15882","volume":"10","author":"H Wu","year":"2011","unstructured":"Wu H, Leng RP. UBE4B, a ubiquitin chain assembly factor, is required for MDM2-mediated p53 polyubiquitination and degradation. Cell Cycle. 2011;10(12):1912\u20135.","journal-title":"Cell Cycle"},{"issue":"6","key":"2225_CR64","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.ccr.2006.10.010","volume":"10","author":"I Ringshausen","year":"2006","unstructured":"Ringshausen I, O\u2019Shea CC, Finch AJ, Swigart LB, Evan GI. Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. Cancer Cell. 2006;10(6):501\u201314.","journal-title":"Cancer Cell"},{"issue":"6","key":"2225_CR65","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1158\/0008-5472.CAN-03-1541","volume":"64","author":"KV Gurova","year":"2004","unstructured":"Gurova KV, Hill JE, Razorenova OV, Chumakov PM, Gudkov AV. p53 pathway in renal cell carcinoma is repressed by a dominant mechanism. Cancer Res. 2004;64(6):1951\u20138.","journal-title":"Cancer Res"},{"issue":"12","key":"2225_CR66","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1158\/0008-5472.CAN-20-3979","volume":"81","author":"H Wu","year":"2021","unstructured":"Wu H, et al. mTOR activation initiates renal cell carcinoma development by coordinating ERK and p38MAPK. Cancer Res. 2021;81(12):3174\u201386.","journal-title":"Cancer Res"},{"issue":"3","key":"2225_CR67","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1038\/cddis.2016.14","volume":"7","author":"JH Kang","year":"2016","unstructured":"Kang JH, et al. Renal cell carcinoma escapes death by p53 depletion through transglutaminase 2-chaperoned autophagy. Cell Death Dis. 2016;7(3):2163.","journal-title":"Cell Death Dis"},{"issue":"3","key":"2225_CR68","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/carcin\/bgy001","volume":"39","author":"H Zhang","year":"2018","unstructured":"Zhang H, et al. p53\u03b2: a new prognostic marker for patients with clear-cell renal cell carcinoma from 5.3 years of median follow-up. Carcinogenesis. 2018;39(3):368\u201374.","journal-title":"Carcinogenesis"},{"issue":"08","key":"2225_CR69","first-page":"921","volume":"122","author":"W Song","year":"2009","unstructured":"Song W, et al. Expression of p53isoforms in renal cell carcinoma. Chin Med J. 2009;122(08):921\u20136.","journal-title":"Chin Med J"},{"issue":"5","key":"2225_CR70","doi-asserted-by":"crossref","first-page":"540","DOI":"10.3892\/etm.2021.9972","volume":"21","author":"D Miricescu","year":"2021","unstructured":"Miricescu D, et al. PI3K\/AKT\/mTOR signalling pathway involvement in renal cell carcinoma pathogenesis (Review). Exp Ther Med. 2021;21(5):540.","journal-title":"Exp Ther Med"},{"issue":"8","key":"2225_CR71","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/ng.2699","volume":"45","author":"Y Sato","year":"2013","unstructured":"Sato Y, et al. Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet. 2013;45(8):860\u20137.","journal-title":"Nat Genet"},{"issue":"2","key":"2225_CR72","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ccr.2007.07.014","volume":"12","author":"J Brugge","year":"2007","unstructured":"Brugge J, Hung MC, Mills GB. A new mutational AKTivation in the PI3K pathway. Cancer Cell. 2007;12(2):104\u20137.","journal-title":"Cancer Cell"},{"issue":"7627","key":"2225_CR73","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nature19796","volume":"539","author":"W Chen","year":"2016","unstructured":"Chen W, et al. Targeting renal cell carcinoma with a HIF-2 antagonist. Nature. 2016;539(7627):112\u20137.","journal-title":"Nature"},{"issue":"18","key":"2225_CR74","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1038\/sj.onc.1206373","volume":"22","author":"M Baba","year":"2003","unstructured":"Baba M, et al. Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through hypoxia-inducible factor. Oncogene. 2003;22(18):2728\u201338.","journal-title":"Oncogene"},{"issue":"1","key":"2225_CR75","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1128\/MCB.24.1.200-216.2004","volume":"24","author":"DC Fingar","year":"2004","unstructured":"Fingar DC, Richardson CJ, Tee AR, Cheatham L, Tsou C, Blenis J. mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1\/eukaryotic translation initiation factor 4E. Mol Cell Biol. 2004;24(1):200\u201316.","journal-title":"Mol Cell Biol"},{"issue":"4","key":"2225_CR76","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.eururo.2015.08.007","volume":"69","author":"J Sch\u00f6del","year":"2016","unstructured":"Sch\u00f6del J, et al. Hypoxia, hypoxia-inducible transcription factors, and renal cancer. Eur Urol. 2016;69(4):646\u201357.","journal-title":"Eur Urol"},{"issue":"20","key":"2225_CR77","doi-asserted-by":"crossref","first-page":"7004","DOI":"10.1128\/MCB.22.20.7004-7014.2002","volume":"22","author":"CC Hudson","year":"2002","unstructured":"Hudson CC, et al. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol. 2002;22(20):7004\u201314.","journal-title":"Mol Cell Biol"},{"issue":"2","key":"2225_CR78","first-page":"240","volume":"1","author":"H Koul","year":"2011","unstructured":"Koul H, et al. Molecular aspects of renal cell carcinoma: a review. Am J Cancer Res. 2011;1(2):240\u201354.","journal-title":"Am J Cancer Res"},{"issue":"2","key":"2225_CR79","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/path.2689","volume":"221","author":"MM Baldewijns","year":"2010","unstructured":"Baldewijns MM, van Vlodrop IJ, Vermeulen PB, Soetekouw PM, van Engeland M, de Bru\u00efne AP. VHL and HIF signalling in renal cell carcinogenesis. J Pathol. 2010;221(2):125\u201338.","journal-title":"J Pathol"},{"issue":"2","key":"2225_CR80","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.pharmthera.2013.12.004","volume":"142","author":"J Polivka Jr","year":"2014","unstructured":"Polivka J Jr, Janku F. Molecular targets for cancer therapy in the PI3K\/AKT\/mTOR pathway. Pharmacol Ther. 2014;142(2):164\u201375.","journal-title":"Pharmacol Ther"},{"issue":"5","key":"2225_CR81","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.cellsig.2009.01.004","volume":"21","author":"RM Memmott","year":"2009","unstructured":"Memmott RM, Dennis PA. Akt-dependent and -independent mechanisms of mTOR regulation in cancer. Cell Signal. 2009;21(5):656\u201364.","journal-title":"Cell Signal"},{"issue":"5712","key":"2225_CR82","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1126\/science.1106148","volume":"307","author":"DD Sarbassov","year":"2005","unstructured":"Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt\/PKB by the rictor-mTOR complex. Science. 2005;307(5712):1098\u2013101.","journal-title":"Science"},{"issue":"13","key":"2225_CR83","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1200\/JCO.2008.20.0766","volume":"27","author":"F Meric-Bernstam","year":"2009","unstructured":"Meric-Bernstam F, Gonzalez-Angulo AM. Targeting the mTOR signaling network for cancer therapy. J Clin Oncol. 2009;27(13):2278\u201387.","journal-title":"J Clin Oncol"},{"key":"2225_CR84","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/978-981-13-1435-3_7","volume":"1088","author":"J Ilha","year":"2018","unstructured":"Ilha J, do Esp\u00edrito-Santo CC, do Freitas GR. mTOR signaling pathway and protein synthesis: from training to aging and muscle autophagy. Adv Exp Med Biol. 2018;1088:139\u201351.","journal-title":"Adv Exp Med Biol"},{"issue":"5","key":"2225_CR85","doi-asserted-by":"crossref","first-page":"431","DOI":"10.3390\/cells8050431","volume":"8","author":"SM Ayuk","year":"2019","unstructured":"Ayuk SM, Abrahamse H. mTOR signaling pathway in cancer targets photodynamic therapy in vitro. Cells. 2019;8(5):431.","journal-title":"Cells"},{"key":"2225_CR86","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.cca.2014.12.041","volume":"444","author":"J Zhang","year":"2015","unstructured":"Zhang J, Yu XH, Yan YG, Wang C, Wang WJ. PI3K\/Akt signaling in osteosarcoma. Clin Chim Acta. 2015;444:182\u201392.","journal-title":"Clin Chim Acta"},{"issue":"6","key":"2225_CR87","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/onc.2013.2","volume":"33","author":"M Gao","year":"2014","unstructured":"Gao M, et al. Site-specific activation of AKT protects cells from death induced by glucose deprivation. Oncogene. 2014;33(6):745\u201355.","journal-title":"Oncogene"},{"issue":"3","key":"2225_CR88","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s12291-017-0713-y","volume":"33","author":"A Kumar","year":"2018","unstructured":"Kumar A, Kumari N, Gupta V, Prasad R. Renal cell carcinoma: molecular aspects. Indian J Clin Biochem. 2018;33(3):246\u201354.","journal-title":"Indian J Clin Biochem"},{"issue":"10","key":"2225_CR89","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.cellsig.2011.05.004","volume":"23","author":"I Hers","year":"2011","unstructured":"Hers I, Vincent EE, Tavar\u00e9 JM. Akt signalling in health and disease. Cell Signal. 2011;23(10):1515\u201327.","journal-title":"Cell Signal"},{"issue":"18","key":"2225_CR90","doi-asserted-by":"crossref","first-page":"10314","DOI":"10.1073\/pnas.171076798","volume":"98","author":"MS Neshat","year":"2001","unstructured":"Neshat MS, et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP\/mTOR. Proc Natl Acad Sci USA. 2001;98(18):10314\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"2225_CR91","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nrurol.2018.9","volume":"15","author":"T Jamaspishvili","year":"2018","unstructured":"Jamaspishvili T, et al. Clinical implications of PTEN loss in prostate cancer. Nat Rev Urol. 2018;15(4):222\u201334.","journal-title":"Nat Rev Urol"},{"issue":"6","key":"2225_CR92","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1158\/0008-5472.CAN-13-1729","volume":"74","author":"A Lin","year":"2014","unstructured":"Lin A, Piao HL, Zhuang L, Sarbassov dos D, Ma L, Gan B. FoxO transcription factors promote AKT Ser473 phosphorylation and renal tumor growth in response to pharmacologic inhibition of the PI3K-AKT pathway. Cancer Res. 2014;74(6):1682\u201393.","journal-title":"Cancer Res"},{"issue":"2","key":"2225_CR93","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/joim.13006","volume":"287","author":"MA Cox","year":"2020","unstructured":"Cox MA, et al. Beyond neurotransmission: acetylcholine in immunity and inflammation. J Intern Med. 2020;287(2):120\u201333.","journal-title":"J Intern Med"},{"issue":"9","key":"2225_CR94","first-page":"4279","volume":"12","author":"P Tie","year":"2022","unstructured":"Tie P, Cheng J, Xue MX, Yin J, Fu G, Duan WL. SLC18A3 promoted renal cancer development through acetylcholine\/cAMP signaling. Am J Cancer Res. 2022;12(9):4279\u201389.","journal-title":"Am J Cancer Res"},{"issue":"7","key":"2225_CR95","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1517\/14728222.2015.1053208","volume":"19","author":"X Wang","year":"2015","unstructured":"Wang X, et al. Decrease of phosphorylated proto-oncogene CREB at Ser 133 site inhibits growth and metastatic activity of renal cell cancer. Expert Opin Ther Targets. 2015;19(7):985\u201395.","journal-title":"Expert Opin Ther Targets"},{"issue":"6","key":"2225_CR96","doi-asserted-by":"crossref","first-page":"4191","DOI":"10.3892\/mmr.2017.6519","volume":"15","author":"X Wang","year":"2017","unstructured":"Wang X, et al. Cyclic AMP responsive element-binding protein induces metastatic renal cell carcinoma by mediating the expression of matrix metallopeptidase-2\/9 and proteins associated with epithelial-mesenchymal transition. Mol Med Rep. 2017;15(6):4191\u20138.","journal-title":"Mol Med Rep"},{"issue":"1","key":"2225_CR97","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1517\/14728220802602349","volume":"13","author":"S Naviglio","year":"2009","unstructured":"Naviglio S, et al. Protein kinase A as a biological target in cancer therapy. Expert Opin Ther Targets. 2009;13(1):83\u201392.","journal-title":"Expert Opin Ther Targets"},{"issue":"1","key":"2225_CR98","doi-asserted-by":"crossref","first-page":"6499","DOI":"10.1038\/s41598-020-63403-y","volume":"10","author":"M Friedrich","year":"2020","unstructured":"Friedrich M, et al. CREB1 is affected by the microRNAs miR-22-3p, miR-26a-5p, miR-27a-3p, and miR-221-3p and correlates with adverse clinicopathological features in renal cell carcinoma. Sci Rep. 2020;10(1):6499.","journal-title":"Sci Rep"},{"issue":"13","key":"2225_CR99","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.3390\/cells11132020","volume":"11","author":"MB Ahmed","year":"2022","unstructured":"Ahmed MB, Alghamdi AAA, Islam SU, Lee JS, Lee YS. cAMP signaling in cancer: a PKA-CREB and EPAC-centric approach. Cells. 2022;11(13):2020.","journal-title":"Cells"},{"key":"2225_CR100","doi-asserted-by":"crossref","unstructured":"Hanusek K, Rybicka B, Pop\u0142awski P, Adamiok-Ostrowska A, G\u0142uchowska K, Piekie\u0142ko-Witkowska A, Bogus\u0142awska J. TGF\u03b21 affects the renal cancer miRNome and regulates tumor cells proliferation. Int J Mol Med. 2022;49(4):1\u20134","DOI":"10.3892\/ijmm.2022.5108"},{"issue":"22","key":"2225_CR101","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1242\/dev.030338","volume":"136","author":"A Moustakas","year":"2009","unstructured":"Moustakas A, Heldin CH. The regulation of TGFbeta signal transduction. Development. 2009;136(22):3699\u2013714.","journal-title":"Development"},{"issue":"12","key":"2225_CR102","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.3390\/cells8121619","volume":"8","author":"J Boguslawska","year":"2019","unstructured":"Boguslawska J, Kryst P, Poletajew S, Piekielko-Witkowska A. TGF-\u03b2 and microRNA interplay in genitourinary cancers. Cells. 2019;8(12):1619.","journal-title":"Cells"},{"issue":"1","key":"2225_CR103","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.bbrc.2013.04.054","volume":"435","author":"AK Bostr\u00f6m","year":"2013","unstructured":"Bostr\u00f6m AK, Lindgren D, Johansson ME, Axelson H. Effects of TGF-\u03b2 signaling in clear cell renal cell carcinoma cells. Biochem Biophys Res Commun. 2013;435(1):126\u201333.","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"2225_CR104","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1002\/jcp.29975","volume":"236","author":"JM Bao","year":"2021","unstructured":"Bao JM, et al. SPARC is a key mediator of TGF-\u03b2-induced renal cancer metastasis. J Cell Physiol. 2021;236(3):1926\u201338.","journal-title":"J Cell Physiol"},{"issue":"3","key":"2225_CR105","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/CCO.0b013e32832a05c8","volume":"21","author":"JA Garcia","year":"2009","unstructured":"Garcia JA, Cowey CL, Godley PA. Renal cell carcinoma. Curr Opin Oncol. 2009;21(3):266\u201371.","journal-title":"Curr Opin Oncol"},{"issue":"2 Pt 1","key":"2225_CR106","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1158\/1078-0432.646.11.2","volume":"11","author":"H S\u00fcltmann","year":"2005","unstructured":"S\u00fcltmann H, et al. Gene expression in kidney cancer is associated with cytogenetic abnormalities, metastasis formation, and patient survival. Clin Cancer Res. 2005;11(2 Pt 1):646\u201355.","journal-title":"Clin Cancer Res"},{"issue":"20","key":"2225_CR107","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1093\/jnci\/94.20.1569","volume":"94","author":"M Yao","year":"2002","unstructured":"Yao M, et al. VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J Natl Cancer Inst. 2002;94(20):1569\u201375.","journal-title":"J Natl Cancer Inst"},{"key":"2225_CR108","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13167-015-0042-2","volume":"6","author":"A Mickley","year":"2015","unstructured":"Mickley A, Kovaleva O, Kzhyshkowska J, Gratchev A. Molecular and immunologic markers of kidney cancer-potential applications in predictive, preventive and personalized medicine. Epma j. 2015;6:20.","journal-title":"Epma j"},{"issue":"8","key":"2225_CR109","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1158\/2326-6066.CIR-20-0532","volume":"9","author":"MV Daugan","year":"2021","unstructured":"Daugan MV, et al. Complement C1s and C4d as prognostic biomarkers in renal cancer: emergence of noncanonical functions of C1s. Cancer Immunol Res. 2021;9(8):891\u2013908.","journal-title":"Cancer Immunol Res"},{"issue":"7","key":"2225_CR110","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1158\/2326-6066.CIR-18-0891","volume":"7","author":"LT Roumenina","year":"2019","unstructured":"Roumenina LT, et al. Tumor Cells Hijack Macrophage-Produced Complement C1q to Promote Tumor Growth. Cancer Immunol Res. 2019;7(7):1091\u2013105.","journal-title":"Cancer Immunol Res"},{"issue":"7","key":"2225_CR111","doi-asserted-by":"crossref","first-page":"e24561","DOI":"10.1097\/MD.0000000000024561","volume":"100","author":"YL Ding","year":"2021","unstructured":"Ding YL, Sun SF, Zhao GL. COL5A2 as a potential clinical biomarker for gastric cancer and renal metastasis. Medicine (Baltimore). 2021;100(7):e24561.","journal-title":"Medicine (Baltimore)"},{"key":"2225_CR112","doi-asserted-by":"crossref","first-page":"107899","DOI":"10.1016\/j.intimp.2021.107899","volume":"99","author":"F Zhang","year":"2021","unstructured":"Zhang F, et al. HJURP is a prognostic biomarker for clear cell renal cell carcinoma and is linked to immune infiltration. Int Immunopharmacol. 2021;99:107899.","journal-title":"Int Immunopharmacol"},{"issue":"10","key":"2225_CR113","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.3390\/cancers13102441","volume":"13","author":"A Cali\u00f2","year":"2021","unstructured":"Cali\u00f2 A, Brunelli M, Gobbo S, Argani P, Munari E, Netto G, Martignoni G, Cathepsin K. A novel diagnostic and predictive biomarker for renal tumors. Cancers. 2021;13(10):2441.","journal-title":"Cancers"},{"issue":"1","key":"2225_CR114","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3390\/cancers14010199","volume":"14","author":"E Arance","year":"2021","unstructured":"Arance E, et al. Determination of exosome mitochondrial DNA as a biomarker of renal cancer aggressiveness. Cancers Basel. 2021;14(1):199.","journal-title":"Cancers Basel"},{"issue":"1","key":"2225_CR115","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1186\/s13046-021-02026-1","volume":"40","author":"F Li","year":"2021","unstructured":"Li F, Aljahdali IAM, Zhang R, Nastiuk KL, Krolewski JJ, Ling X. Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1\u03b1, HIF2\u03b1, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma. J Exp Clin Cancer Res. 2021;40(1):254.","journal-title":"J Exp Clin Cancer Res"},{"issue":"12","key":"2225_CR116","doi-asserted-by":"crossref","first-page":"7037","DOI":"10.21873\/anticanres.14730","volume":"40","author":"V Gebbia","year":"2020","unstructured":"Gebbia V, et al. Stereotactic radiotherapy for the treatment of patients with oligo-progressive metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitor: data from the real world. Anticancer Res. 2020;40(12):7037\u201343.","journal-title":"Anticancer Res"},{"key":"2225_CR117","first-page":"1","volume":"41","author":"AL Schmidt","year":"2021","unstructured":"Schmidt AL, Tabakin AL, Singer EA, Choueiri TK, McKay RR. Next steps: sequencing therapies in metastatic kidney cancer in the contemporary era. Am Soc Clin Oncol Educ Book. 2021;41:1\u201311.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"3","key":"2225_CR118","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0022-5347(17)62331-0","volume":"101","author":"CJ Robson","year":"1969","unstructured":"Robson CJ, Churchill BM, Anderson W. The results of radical nephrectomy for renal cell carcinoma. J Urol. 1969;101(3):297\u2013301.","journal-title":"J Urol"},{"issue":"5","key":"2225_CR119","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1016\/j.juro.2006.07.033","volume":"176","author":"S Permpongkosol","year":"2006","unstructured":"Permpongkosol S, Bagga HS, Romero FR, Sroka M, Jarrett TW, Kavoussi LR. Laparoscopic versus open partial nephrectomy for the treatment of pathological T1N0M0 renal cell carcinoma: a 5-year survival rate. J Urol. 2006;176(5):1984\u20138 (discussion 1988-9).","journal-title":"J Urol"},{"key":"2225_CR120","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1471-2490-12-11","volume":"12","author":"RL Kyllo","year":"2012","unstructured":"Kyllo RL, et al. Prospective multi-center study of oncologic outcomes of robot-assisted partial nephrectomy for pT1 renal cell carcinoma. BMC Urol. 2012;12:11.","journal-title":"BMC Urol"},{"issue":"9286","key":"2225_CR121","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S0140-6736(01)06103-7","volume":"358","author":"GH Mickisch","year":"2001","unstructured":"Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001;358(9286):966\u201370.","journal-title":"Lancet"},{"issue":"23","key":"2225_CR122","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMoa003013","volume":"345","author":"RC Flanigan","year":"2001","unstructured":"Flanigan RC, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345(23):1655\u20139.","journal-title":"N Engl J Med"},{"issue":"1","key":"2225_CR123","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1055\/s-0033-1363840","volume":"31","author":"LM Krabbe","year":"2014","unstructured":"Krabbe LM, Bagrodia A, Margulis V, Wood CG. Surgical management of renal cell carcinoma. Semin Intervent Radiol. 2014;31(1):27\u201332.","journal-title":"Semin Intervent Radiol"},{"issue":"11","key":"2225_CR124","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/j.clinthera.2006.11.015","volume":"28","author":"T Shih","year":"2006","unstructured":"Shih T, Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther. 2006;28(11):1779\u2013802.","journal-title":"Clin Ther"},{"issue":"2","key":"2225_CR125","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.canlet.2013.09.038","volume":"343","author":"J Mattei","year":"2014","unstructured":"Mattei J, da Silva RD, Sehrt D, Molina WR, Kim FJ. Targeted therapy in metastatic renal carcinoma. Cancer Lett. 2014;343(2):156\u201360.","journal-title":"Cancer Lett"},{"issue":"1","key":"2225_CR126","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.semnephrol.2019.12.004","volume":"40","author":"JJ Huang","year":"2020","unstructured":"Huang JJ, Hsieh JJ. The therapeutic landscape of renal cell carcinoma: from the dark age to the golden age. Semin Nephrol. 2020;40(1):28\u201341.","journal-title":"Semin Nephrol"},{"issue":"8","key":"2225_CR127","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1177\/1756287217713902","volume":"9","author":"M Rizzo","year":"2017","unstructured":"Rizzo M, Porta C. Sunitinib in the treatment of renal cell carcinoma: an update on recent evidence. Ther Adv Urol. 2017;9(8):195\u2013207.","journal-title":"Ther Adv Urol"},{"issue":"2","key":"2225_CR128","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","volume":"356","author":"RJ Motzer","year":"2007","unstructured":"Motzer RJ, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115\u201324.","journal-title":"N Engl J Med"},{"issue":"7","key":"2225_CR129","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1200\/JCO.2006.06.3602","volume":"25","author":"LQ Chow","year":"2007","unstructured":"Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol. 2007;25(7):884\u201396.","journal-title":"J Clin Oncol"},{"issue":"6","key":"2225_CR130","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1517\/13543780902980171","volume":"18","author":"HK Gan","year":"2009","unstructured":"Gan HK, Seruga B, Knox JJ. Sunitinib in solid tumors. Expert Opin Invest Drugs. 2009;18(6):821\u201334.","journal-title":"Expert Opin Invest Drugs"},{"issue":"8","key":"2225_CR131","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.2217\/fon.14.274","volume":"11","author":"SJ Welsh","year":"2015","unstructured":"Welsh SJ, Fife K. Pazopanib for the treatment of renal cell carcinoma. Future Oncol. 2015;11(8):1169\u201379.","journal-title":"Future Oncol"},{"issue":"5","key":"2225_CR132","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1517\/14740338.2012.712108","volume":"11","author":"A Zivi","year":"2012","unstructured":"Zivi A, Cerbone L, Recine F, Sternberg CN. Safety and tolerability of pazopanib in the treatment of renal cell carcinoma. Expert Opin Drug Saf. 2012;11(5):851\u20139.","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"2225_CR133","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2165\/11591240-000000000-00000","volume":"11","author":"B Escudier","year":"2011","unstructured":"Escudier B, Gore M. Axitinib for the management of metastatic renal cell carcinoma. Drugs R D. 2011;11(2):113\u201326.","journal-title":"Drugs R D"},{"issue":"16","key":"2225_CR134","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1007\/s40265-015-0483-x","volume":"75","author":"GM Keating","year":"2015","unstructured":"Keating GM. Axitinib: a review in advanced renal cell carcinoma. Drugs. 2015;75(16):1903\u201313.","journal-title":"Drugs"},{"issue":"1","key":"2225_CR135","doi-asserted-by":"crossref","first-page":"107327481878936","DOI":"10.1177\/1073274818789361","volume":"25","author":"K Suyama","year":"2018","unstructured":"Suyama K, Iwase H. Lenvatinib: a promising molecular targeted agent for multiple cancers. Cancer Control. 2018;25(1):1073274818789361.","journal-title":"Cancer Control"},{"issue":"12","key":"2225_CR136","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","volume":"10","author":"FM Yakes","year":"2011","unstructured":"Yakes FM, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther. 2011;10(12):2298\u2013308.","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"2225_CR137","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11864-017-0444-6","volume":"18","author":"A Abdelaziz","year":"2017","unstructured":"Abdelaziz A, Vaishampayan U. Cabozantinib for renal cell carcinoma: current and future paradigms. Curr Treat Opt Oncol. 2017;18(3):18.","journal-title":"Curr Treat Opt Oncol"},{"issue":"18","key":"2225_CR138","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJM199804303381805","volume":"338","author":"S Negrier","year":"1998","unstructured":"Negrier S, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Fran\u00e7ais d\u2019Immunoth\u00e9rapie. N Engl J Med. 1998;338(18):1272\u20138.","journal-title":"N Engl J Med"},{"issue":"1","key":"2225_CR139","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3892\/ol.2022.13355","volume":"24","author":"W Shi","year":"2022","unstructured":"Shi W, Yao X, Fu Y, Wang Y. Interferon-\u03b1 and its effects on cancer cell apoptosis. Oncol Lett. 2022;24(1):235.","journal-title":"Oncol Lett"},{"issue":"3","key":"2225_CR140","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1200\/JCO.1995.13.3.688","volume":"13","author":"G Fyfe","year":"1995","unstructured":"Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995;13(3):688\u201396.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2225_CR141","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1200\/JCO.2005.03.206","volume":"23","author":"DF McDermott","year":"2005","unstructured":"McDermott DF, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol. 2005;23(1):133\u201341.","journal-title":"J Clin Oncol"},{"issue":"16","key":"2225_CR142","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1200\/JCO.2003.02.122","volume":"21","author":"JC Yang","year":"2003","unstructured":"Yang JC, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol. 2003;21(16):3127\u201332.","journal-title":"J Clin Oncol"},{"issue":"2","key":"2225_CR143","doi-asserted-by":"crossref","first-page":"55","DOI":"10.15586\/jkcvhl.2015.24","volume":"2","author":"H Kawashima","year":"2015","unstructured":"Kawashima H, Kimura Y. Present and future perspectives on immunotherapy for advanced renal cell carcinoma: Going to the core or beating around the bush? J Kidney Cancer VHL. 2015;2(2):55\u201363.","journal-title":"J Kidney Cancer VHL"},{"issue":"4","key":"2225_CR144","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252\u201364.","journal-title":"Nat Rev Cancer"},{"key":"2225_CR145","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3389\/fonc.2018.00086","volume":"8","author":"JA Seidel","year":"2018","unstructured":"Seidel JA, Otsuka A, Kabashima K. Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations. Front Oncol. 2018;8:86.","journal-title":"Front Oncol"},{"issue":"12","key":"2225_CR146","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.2174\/1871530321666210310142141","volume":"21","author":"M Mohsenzadegan","year":"2021","unstructured":"Mohsenzadegan M, et al. The potential of T cell immunoglobulin and mucin-domain containing-3 (Tim-3) in designing novel immunotherapy for bladder cancer. Endocr Metab Immune Disord Drug Targets. 2021;21(12):2131\u201346.","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"issue":"22","key":"2225_CR147","doi-asserted-by":"crossref","first-page":"5856","DOI":"10.3390\/cancers13225856","volume":"13","author":"MC Kim","year":"2021","unstructured":"Kim MC, et al. Updates on immunotherapy and immune landscape in renal clear cell carcinoma. Cancers (Basel). 2021;13(22):5856.","journal-title":"Cancers (Basel)"},{"issue":"10","key":"2225_CR148","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1007\/s00432-012-1237-8","volume":"138","author":"C Sun","year":"2012","unstructured":"Sun C, et al. CD133 expression in renal cell carcinoma (RCC) is correlated with nuclear hypoxia-inducing factor 1\u03b1 (HIF-1\u03b1). J Cancer Res Clin Oncol. 2012;138(10):1619\u201324.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"10","key":"2225_CR149","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1111\/j.1600-6143.2012.04224.x","volume":"12","author":"LV Riella","year":"2012","unstructured":"Riella LV, Paterson AM, Sharpe AH, Chandraker A. Role of the PD-1 pathway in the immune response. Am J Transplant. 2012;12(10):2575\u201387.","journal-title":"Am J Transplant"},{"issue":"3","key":"2225_CR150","first-page":"727","volume":"10","author":"Y Han","year":"2020","unstructured":"Han Y, Liu D, Li L. PD-1\/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 2020;10(3):727\u201342.","journal-title":"Am J Cancer Res"},{"issue":"4","key":"2225_CR151","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1200\/JCO.22.02270","volume":"41","author":"JR Brahmer","year":"2023","unstructured":"Brahmer JR, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2023;41(4):715\u201323.","journal-title":"J Clin Oncol"},{"issue":"Suppl 8","key":"2225_CR152","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/jdv.15992","volume":"33","author":"MC Liebl","year":"2019","unstructured":"Liebl MC, Hofmann TG. Identification of responders to immune checkpoint therapy: which biomarkers have the highest value? J Eur Acad Dermatol Venereol. 2019;33(Suppl 8):52\u20136.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"2225_CR153","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","volume":"380","author":"BI Rini","year":"2019","unstructured":"Rini BI, et al. Pembrolizumab plus Axitinib versus Sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1116\u201327.","journal-title":"N Engl J Med"},{"issue":"3","key":"2225_CR154","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(15)70054-9","volume":"16","author":"NA Rizvi","year":"2015","unstructured":"Rizvi NA, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015;16(3):257\u201365.","journal-title":"Lancet Oncol"},{"issue":"1","key":"2225_CR155","doi-asserted-by":"crossref","first-page":"11472","DOI":"10.1038\/s41598-019-47910-1","volume":"9","author":"A De Sousa Linhares","year":"2019","unstructured":"De Sousa Linhares A, et al. Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1\/PD-L1 signaling. Sci Rep. 2019;9(1):11472.","journal-title":"Sci Rep"},{"issue":"7528","key":"2225_CR156","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","volume":"515","author":"RS Herbst","year":"2014","unstructured":"Herbst RS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563\u20137.","journal-title":"Nature"},{"issue":"12","key":"2225_CR157","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/70932","volume":"5","author":"H Dong","year":"1999","unstructured":"Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med. 1999;5(12):1365\u20139.","journal-title":"Nat Med"},{"issue":"6","key":"2225_CR158","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41571-021-00473-5","volume":"18","author":"DB Doroshow","year":"2021","unstructured":"Doroshow DB, et al. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2021;18(6):345\u201362.","journal-title":"Nat Rev Clin Oncol"},{"issue":"30","key":"2225_CR159","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.2217\/fon-2019-0348","volume":"15","author":"JC Simeone","year":"2019","unstructured":"Simeone JC, Nordstrom BL, Patel K, Klein AB. Treatment patterns and overall survival in metastatic non-small-cell lung cancer in a real-world, US setting. Future Oncol. 2019;15(30):3491\u2013502.","journal-title":"Future Oncol"},{"issue":"9","key":"2225_CR160","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1158\/2326-6066.CIR-14-0191","volume":"3","author":"R Stewart","year":"2015","unstructured":"Stewart R, et al. Identification and characterization of MEDI4736, an antagonistic anti-PD-L1 monoclonal antibody. Cancer Immunol Res. 2015;3(9):1052\u201362.","journal-title":"Cancer Immunol Res"},{"issue":"26","key":"2225_CR161","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.2016.67.9761","volume":"34","author":"C Massard","year":"2016","unstructured":"Massard C, et al. Safety and efficacy of Durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol. 2016;34(26):3119\u201325.","journal-title":"J Clin Oncol"},{"issue":"4","key":"2225_CR162","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1080\/21645515.2018.1551671","volume":"15","author":"JM Collins","year":"2019","unstructured":"Collins JM, Gulley JL. Product review: avelumab, an anti-PD-L1 antibody. Hum Vaccin Immunother. 2019;15(4):891\u2013908.","journal-title":"Hum Vaccin Immunother"},{"issue":"4","key":"2225_CR163","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S1470-2045(18)30107-4","volume":"19","author":"TK Choueiri","year":"2018","unstructured":"Choueiri TK, et al. Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial. Lancet Oncol. 2018;19(4):451\u201360.","journal-title":"Lancet Oncol"},{"issue":"15_suppl","key":"2225_CR164","doi-asserted-by":"crossref","first-page":"4580","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS4580","volume":"34","author":"JMG Larkin","year":"2016","unstructured":"Larkin JMG, et al. Avelumab (MSB0010718C; anti-PD-L1) in combination with axitinib as first-line treatment for patients with advanced renal cell carcinoma. J Clin Oncol. 2016;34(15_suppl):4580.","journal-title":"J Clin Oncol"},{"issue":"14","key":"2225_CR165","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.22.01414","volume":"41","author":"C Su\u00e1rez","year":"2023","unstructured":"Su\u00e1rez C, et al. Phase II study investigating the safety and efficacy of Savolitinib and Durvalumab in metastatic papillary renal cancer (CALYPSO). J Clin Oncol. 2023;41(14):2493\u2013502.","journal-title":"J Clin Oncol"},{"issue":"14","key":"2225_CR166","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1158\/1078-0432.CCR-21-4115","volume":"28","author":"MH Voss","year":"2022","unstructured":"Voss MH, et al. A randomized phase II study of MEDI0680 in Combination with Durvalumab versus Nivolumab monotherapy in patients with advanced or metastatic clear-cell renal cell carcinoma. Clin Cancer Res. 2022;28(14):3032\u201341.","journal-title":"Clin Cancer Res"},{"issue":"13","key":"2225_CR167","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1200\/JCO.2009.26.7849","volume":"28","author":"B Escudier","year":"2010","unstructured":"Escudier B, et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol. 2010;28(13):2144\u201350.","journal-title":"J Clin Oncol"},{"issue":"2","key":"2225_CR168","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","volume":"356","author":"B Escudier","year":"2007","unstructured":"Escudier B, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356(2):125\u201334.","journal-title":"N Engl J Med"},{"issue":"27","key":"2225_CR169","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.1200\/JCO.2008.21.7034","volume":"27","author":"BI Rini","year":"2009","unstructured":"Rini BI, et al. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol. 2009;27(27):4462\u20138.","journal-title":"J Clin Oncol"},{"issue":"19","key":"2225_CR170","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, et al. Nivolumab versus Everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803\u201313.","journal-title":"N Engl J Med"},{"issue":"8","key":"2225_CR171","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.annonc.2020.04.010","volume":"31","author":"TK Choueiri","year":"2020","unstructured":"Choueiri TK, et al. Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. Ann Oncol. 2020;31(8):1030\u20139.","journal-title":"Ann Oncol"},{"issue":"12","key":"2225_CR172","doi-asserted-by":"crossref","first-page":"e731","DOI":"10.1016\/S1470-2045(17)30607-1","volume":"18","author":"NL Syn","year":"2017","unstructured":"Syn NL, Teng MWL, Mok TSK, Soo RA. De-novo and acquired resistance to immune checkpoint targeting. Lancet Oncol. 2017;18(12):e731\u201341.","journal-title":"Lancet Oncol"},{"issue":"8","key":"2225_CR173","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nrd4591","volume":"14","author":"KM Mahoney","year":"2015","unstructured":"Mahoney KM, Rennert PD, Freeman GJ. Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov. 2015;14(8):561\u201384.","journal-title":"Nat Rev Drug Discov"},{"issue":"6127","key":"2225_CR174","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/328267a0","volume":"328","author":"JF Brunet","year":"1987","unstructured":"Brunet JF, et al. A new member of the immunoglobulin superfamily\u2013CTLA-4. Nature. 1987;328(6127):267\u201370.","journal-title":"Nature"},{"issue":"1","key":"2225_CR175","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1600-065X.2009.00770.x","volume":"229","author":"CE Rudd","year":"2009","unstructured":"Rudd CE, Taylor A, Schneider H. CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol Rev. 2009;229(1):12\u201326.","journal-title":"Immunol Rev"},{"issue":"5071","key":"2225_CR176","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1126\/science.1496399","volume":"257","author":"PS Linsley","year":"1992","unstructured":"Linsley PS, et al. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science. 1992;257(5071):792\u20135.","journal-title":"Science"},{"issue":"1","key":"2225_CR177","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1074-7613(01)00259-X","volume":"16","author":"JG Egen","year":"2002","unstructured":"Egen JG, Allison JP. Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength. Immunity. 2002;16(1):23\u201335.","journal-title":"Immunity"},{"issue":"11","key":"2225_CR178","first-page":"739","volume":"14","author":"A Mullard","year":"2015","unstructured":"Mullard A. FDA approves first immunotherapy combo. Nat Rev Drug Discov. 2015;14(11):739\u2013739.","journal-title":"Nat Rev Drug Discov"},{"key":"2225_CR179","doi-asserted-by":"crossref","first-page":"v405","DOI":"10.1093\/annonc\/mdx376.007","volume":"28","author":"J Powderly","year":"2017","unstructured":"Powderly J, et al. CA-170, a first in class oral small molecule dual inhibitor of immune checkpoints PD-L1 and VISTA, demonstrates tumor growth inhibition in pre-clinical models and promotes T cell activation in Phase 1 study. Ann Oncol. 2017;28:v405\u20136.","journal-title":"Ann Oncol"},{"issue":"2","key":"2225_CR180","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/cncr.23552","volume":"113","author":"JA Klapper","year":"2008","unstructured":"Klapper JA, et al. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma\u202f: a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer. 2008;113(2):293\u2013301.","journal-title":"Cancer"},{"issue":"3","key":"2225_CR181","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1158\/1078-0432.CCR-15-1631","volume":"22","author":"DH Charych","year":"2016","unstructured":"Charych DH, et al. NKTR-214, an engineered cytokine with biased IL2 receptor binding, increased tumor exposure, and marked efficacy in mouse tumor models. Clin Cancer Res. 2016;22(3):680\u201390.","journal-title":"Clin Cancer Res"},{"issue":"15_suppl","key":"2225_CR182","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1200\/JCO.2018.36.15_suppl.3006","volume":"36","author":"A Diab","year":"2018","unstructured":"Diab A, et al. NKTR-214 (CD122-biased agonist) plus nivolumab in patients with advanced solid tumors: Preliminary phase 1\/2 results of PIVOT. J Clin Oncol. 2018;36(15_suppl):3006.","journal-title":"J Clin Oncol."},{"issue":"2","key":"2225_CR183","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/cdd.2014.134","volume":"22","author":"S Tugues","year":"2015","unstructured":"Tugues S, et al. New insights into IL-12-mediated tumor suppression. Cell Death Differ. 2015;22(2):237\u201346.","journal-title":"Cell Death Differ"},{"issue":"2","key":"2225_CR184","first-page":"123","volume":"17","author":"AD Janiszewska","year":"2013","unstructured":"Janiszewska AD, Poletajew S, Wasiuty\u0144ski A. Spontaneous regression of renal cell carcinoma. Contemp Oncol (Pozn). 2013;17(2):123\u20137.","journal-title":"Contemp Oncol (Pozn)"},{"key":"2225_CR185","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ejca.2018.02.012","volume":"94","author":"TK Choueiri","year":"2018","unstructured":"Choueiri TK, et al. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): progression-free survival by independent review and overall survival update. Eur J Cancer. 2018;94:115\u201325.","journal-title":"Eur J Cancer"},{"issue":"8","key":"2225_CR186","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1470-2045(09)70162-7","volume":"10","author":"ME Gore","year":"2009","unstructured":"Gore ME, et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol. 2009;10(8):757\u201363.","journal-title":"Lancet Oncol"},{"issue":"Suppl 1","key":"2225_CR187","first-page":"S55","volume":"6","author":"RI Fisher","year":"2000","unstructured":"Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am. 2000;6(Suppl 1):S55\u20137.","journal-title":"Cancer J Sci Am"},{"issue":"1","key":"2225_CR188","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s40425-019-0567-3","volume":"7","author":"M Fishman","year":"2019","unstructured":"Fishman M, et al. Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIM(SM) registry. J Immunother Cancer. 2019;7(1):84.","journal-title":"J Immunother Cancer"},{"issue":"10189","key":"2225_CR189","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1016\/S0140-6736(19)30723-8","volume":"393","author":"BI Rini","year":"2019","unstructured":"Rini BI, et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet. 2019;393(10189):2404\u201315.","journal-title":"Lancet"},{"issue":"11","key":"2225_CR190","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.6004\/jnccn.2019.0054","volume":"17","author":"RJ Motzer","year":"2019","unstructured":"Motzer RJ, et al. NCCN Guidelines Insights: kidney cancer, version 2.2020. J Natl Compr Cancer Netw. 2019;17(11):1278\u201385.","journal-title":"J Natl Compr Cancer Netw"},{"issue":"2","key":"2225_CR191","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.eururo.2019.05.022","volume":"76","author":"L Albiges","year":"2019","unstructured":"Albiges L, et al. Updated European Association of Urology Guidelines on renal cell carcinoma: immune checkpoint inhibition is the new backbone in first-line treatment of metastatic clear-cell renal cell carcinoma. Eur Urol. 2019;76(2):151\u20136.","journal-title":"Eur Urol"},{"issue":"12","key":"2225_CR192","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","volume":"380","author":"RJ Motzer","year":"2019","unstructured":"Motzer RJ, et al. Avelumab plus Axitinib versus Sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1103\u201315.","journal-title":"N Engl J Med"},{"issue":"7","key":"2225_CR193","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S1470-2045(22)00290-X","volume":"23","author":"RJ Motzer","year":"2022","unstructured":"Motzer RJ, et al. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. Lancet Oncol. 2022;23(7):888\u201398.","journal-title":"Lancet Oncol"},{"issue":"14","key":"2225_CR194","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer RJ, et al. Nivolumab plus Ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378(14):1277\u201390.","journal-title":"N Engl J Med"},{"issue":"6_suppl","key":"2225_CR195","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1200\/JCO.2018.36.6_suppl.618","volume":"36","author":"B Escudier","year":"2018","unstructured":"Escudier B, Barthelemy P, Ravaud A, Negrier S, Needle MN, Albiges L. Tivozanib combined with nivolumab: Phase Ib\/II study in metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2018;36(6_suppl):618.","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"2225_CR196","doi-asserted-by":"crossref","first-page":"5010","DOI":"10.1200\/jco.2014.32.15_suppl.5010","volume":"32","author":"A Amin","year":"2014","unstructured":"Amin A, et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2014;32(15_suppl):5010.","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"2225_CR197","doi-asserted-by":"crossref","first-page":"4506","DOI":"10.1200\/JCO.2017.35.15_suppl.4506","volume":"35","author":"S Chowdhury","year":"2017","unstructured":"Chowdhury S, et al. A phase I\/II study to assess the safety and efficacy of pazopanib (PAZ) and pembrolizumab (PEM) in patients (pts) with advanced renal cell carcinoma (aRCC). J Clin Oncol. 2017;35(15_suppl):4506.","journal-title":"J Clin Oncol"},{"issue":"7","key":"2225_CR198","doi-asserted-by":"crossref","first-page":"e948","DOI":"10.1002\/ctm2.948","volume":"12","author":"L Meza","year":"2022","unstructured":"Meza L, Govindarajan A, Feng M, Pal SK. Live bacterial supplementation for improving treatment response in metastatic renal cell carcinoma. Clin Transl Med. 2022;12(7):e948.","journal-title":"Clin Transl Med"},{"issue":"4","key":"2225_CR199","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/s41591-022-01694-6","volume":"28","author":"N Dizman","year":"2022","unstructured":"Dizman N, et al. Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial. Nat Med. 2022;28(4):704\u201312.","journal-title":"Nat Med"},{"issue":"2","key":"2225_CR200","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.eururo.2020.04.044","volume":"78","author":"L Derosa","year":"2020","unstructured":"Derosa L, et al. Gut bacteria composition drives primary resistance to cancer immunotherapy in renal cell carcinoma patients. Eur Urol. 2020;78(2):195\u2013206.","journal-title":"Eur Urol"},{"issue":"4","key":"2225_CR201","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.jcmgh.2021.06.001","volume":"12","author":"JA Owens","year":"2021","unstructured":"Owens JA, et al. Lactobacillus rhamnosus GG orchestrates an antitumor immune response. Cell Mol Gastroenterol Hepatol. 2021;12(4):1311\u201327.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"5","key":"2225_CR202","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.cmet.2021.03.002","volume":"33","author":"Y He","year":"2021","unstructured":"He Y, et al. Gut microbial metabolites facilitate anticancer therapy efficacy by modulating cytotoxic CD8(+) T cell immunity. Cell Metab. 2021;33(5):988-1000.e7.","journal-title":"Cell Metab"},{"issue":"6371","key":"2225_CR203","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.aan3706","volume":"359","author":"B Routy","year":"2018","unstructured":"Routy B, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359(6371):91\u20137.","journal-title":"Science"},{"issue":"1","key":"2225_CR204","doi-asserted-by":"crossref","first-page":"131","DOI":"10.21037\/tau.2017.01.12","volume":"6","author":"O Cuvillier","year":"2017","unstructured":"Cuvillier O. The therapeutic potential of HIF-2 antagonism in renal cell carcinoma. Transl Androl Urol. 2017;6(1):131\u20133.","journal-title":"Transl Androl Urol"},{"issue":"15","key":"2225_CR205","doi-asserted-by":"crossref","first-page":"4509","DOI":"10.1200\/JCO.2021.39.15_suppl.4509","volume":"39","author":"C-H Lee","year":"2021","unstructured":"Lee C-H, et al. Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Results of a phase 2 trial. J Clin Oncol. 2021;39(15):4509.","journal-title":"J Clin Oncol"},{"issue":"15_Suppl","key":"2225_CR206","doi-asserted-by":"crossref","first-page":"5003","DOI":"10.1200\/JCO.2020.38.15_suppl.5003","volume":"38","author":"E Jonasch","year":"2020","unstructured":"Jonasch E, et al. Phase II study of the oral HIF-2\u03b1 inhibitor MK-6482 for Von Hippel-Lindau disease\u2013associated renal cell carcinoma. J Clin Oncol. 2020;38(15_Suppl):5003.","journal-title":"J Clin Oncol."},{"issue":"10397","key":"2225_CR207","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0140-6736(23)00922-4","volume":"402","author":"SK Pal","year":"2023","unstructured":"Pal SK, et al. Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2023;402(10397):185\u201395.","journal-title":"Lancet"},{"issue":"6_Suppl","key":"2225_CR208","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1200\/JCO.2020.38.6_suppl.TPS767","volume":"38","author":"TK Choueiri","year":"2020","unstructured":"Choueiri TK, Albiges L, Powles T, Scheffold C, Wang F, Motzer RJ. A phase III study (COSMIC-313) of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in patients (pts) with previously untreated advanced renal cell carcinoma (aRCC) of intermediate or poor risk. J Clin Oncol. 2020;38(6_Suppl):767.","journal-title":"J Clin Oncol"},{"issue":"6_Suppl","key":"2225_CR209","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1200\/JCO.2021.39.6_suppl.TPS366","volume":"39","author":"T Zhang","year":"2021","unstructured":"Zhang T, et al. PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704). J Clin Oncol. 2021;39(6_Suppl):366.","journal-title":"J Clin Oncol."},{"issue":"6_Suppl","key":"2225_CR210","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1200\/JCO.2020.38.6_suppl.TPS763","volume":"38","author":"NM Tannir","year":"2020","unstructured":"Tannir NM, et al. PIVOT-09: A phase III randomized open-label study of bempegaldesleukin (NKTR-214) plus nivolumab versus sunitinib or cabozantinib (investigator\u2019s choice) in patients with previously untreated advanced renal cell carcinoma (RCC). J Clin Oncol. 2020;38(6_Suppl):763.","journal-title":"J Clin Oncol."},{"issue":"9","key":"2225_CR211","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1080\/14656566.2016.1182987","volume":"17","author":"VS Koshkin","year":"2016","unstructured":"Koshkin VS, Rini BI. Emerging therapeutics in refractory renal cell carcinoma. Expert Opin Pharmacother. 2016;17(9):1225\u201332.","journal-title":"Expert Opin Pharmacother"},{"issue":"10","key":"2225_CR212","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1016\/j.celrep.2016.02.024","volume":"14","author":"F Chen","year":"2016","unstructured":"Chen F, et al. Multilevel genomics-based taxonomy of renal cell carcinoma. Cell Rep. 2016;14(10):2476\u201389.","journal-title":"Cell Rep"},{"issue":"6","key":"2225_CR213","doi-asserted-by":"crossref","first-page":"507","DOI":"10.3322\/caac.21411","volume":"67","author":"PC Barata","year":"2017","unstructured":"Barata PC, Rini BI. Treatment of renal cell carcinoma: current status and future directions. CA Cancer J Clin. 2017;67(6):507\u201324.","journal-title":"CA Cancer J Clin"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-023-02225-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-023-02225-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-023-02225-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T16:39:30Z","timestamp":1700584770000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-023-02225-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,13]]},"references-count":213,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2225"],"URL":"https:\/\/doi.org\/10.1007\/s12032-023-02225-0","relation":{},"ISSN":["1559-131X"],"issn-type":[{"type":"electronic","value":"1559-131X"}],"subject":[],"published":{"date-parts":[[2023,11,13]]},"assertion":[{"value":"5 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that the research was conducted without any commercial or financial relationships that could be construed as a potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"We assure you this manuscript has not been published in part or whole and is not under consideration for publication elsewhere in any language. All the authors have thoroughly studied the manuscript and approved its consent and submission to the \"Medical Oncology\" journal.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"355"}}